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Abstract
Objectives Pantoprazole is metabolized by cytochrome P450
2 C19, which shows genetic polymorphism. The effect of
CYP2C19 polymorphism on single-dose pharmacokinetics
of oral pantoprazole in healthy volunteers was evaluated.
Methods Pantoprazole pharmacokinetics was determined in
32 healthy volunteers after a 40-mg single oral dose of the
drug.
Results Carriers of CYP2C19*2/*2 (n02) were characterized
by higher, starting from 3.5 h post dose, plasma concentrations
of pantoprazole in comparison to wild-type (CYP2C19*1/*1,
n06) volunteers. In subjects withCYP2C19*17/*17 genotype
(n06) significantly lower plasma concentrations of the drug
vs CYP2C19*1/*1 carriers, were observed from 3.0 h after
oral pantoprazole administration. Carriers ofCYP2C19*1/*17
(n06) and CYP2C19*2/*17 (n06) displayed concentration–
time profiles comparable to wild-type subjects. CYP2C19*2/
*2 volunteers showed a decrease in terminal elimination rate
constant (1z) by 83.3%, prolongation of terminal half-life (t½)
by 572%, a rise in area under the concentration–time curve
(AUC) and mean residence time (MRT) by 506% and 259%
respectively. Heterozygotes, i.e.. CYP2C19*1/*2 vs
CYP2C19*1/*1 were characterized by higher AUC (4.38±
1.00 mg⋅h/L vs 3.00±1.02 mg⋅h/L, p<0.05) and Cmax (2.13±
0.42 mg/L vs 1.61±0.35 mg/L, p<0.05) respectively. A sig-
nificant reduction in MRT (3.83±0.82 h vs 2.73±0.23 h,
p<0.05) in carriers of CYP2C19*17/*17 vs CYP2C19*1/*1
genotypes was observed. Population modeling confirmed the
influence of *1/*2, *2/*2, and *17/*17 genotypes on the
pharmacokinetics of pantoprazole. The lowest population oral
clearance was assessed in the carriers of genotype *2/*2
(3.68 L/h) and the highest value in subjects with genotype
*17/*17 (31.13 L/h).
Conclusion These data suggest that CYP2C19 polymorphism
is an important determinant of pantoprazole pharmacokinetics.
Keywords CYP2C19 polymorphism . Pantoprazole .
Pharmacokinetics
Introduction
CYP2C19 is an important drug-metabolizing enzyme
encoded by a highly polymorphic gene, with the two most
frequent allelic variants in Caucasian populations,
CYP2C19*2 andCYP2C19*17. Population studies have dem-
onstrated that subjects homozygous for the inactivating allele
CYP2C19*2 associated with a splicing defect are phenotypi-
cally poor metabolizers of CYP2C19 substrates [1, 2]. Poor
metabolizers are found in 3–5% of Caucasians, and much
more frequently in Asian populations, i.e., 12–23% [3]. The
CYP2C19*17 allele was documented to correlate with high
CYP2C19 activity [4]. In European populations the
CYP2C19*17 allele is found in 18–28% of subjects, in 17–
18% of Africans and 0.3–4% in Asian populations [5].
Proton pump inhibitors (PPI), among them pantoprazole,
are the mainstays in the treatment of gastric acid-related dis-
orders. It was documented that the pharmacokinetics of PPI as
well as the clinical outcome of treatment are associated with
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CYP2C19 polymorphism, being their main metabolizing en-
zyme. However, the effect of CYP2C19 on pantoprazole
metabolism was not as extensively studied as in the case of
omeprazole. Tanaka et al. reported that in poor CYP2C19
metabolizers metabolism of R(+)-pantoprazole was impaired
to a greater extent than that of S(-)-pantoprazole [6]. Some
studies on the effects of the CYP2C19 polymorphism on
pantoprazole kinetics revealed an association of drug pharma-
cokinetics and genotypes in adults and children [7–9]. How-
ever, these studies were carried out on a limited number of
cases and did not involve CYP2C19*17/*17 homozygotes,
which seems to be an important determinant in pantoprazole
metabolism.
Our previous preliminary study also suggested an impact of
the CYP2C19 polymorphism on pantoprazole metabolism. It
was found that concentrations of the drug at 3 h post-oral dose
were the highest in heterozygous subjects, carriers of
CYP2C19*1/*2 genotypes (unfortunately, we were not able
to measure pantoprazole concentrations in CYP2C19*2/*2
patients), and the lowest in the case of CYP2C19*17/*17
subjects [10]. Therefore, it was decided to study an association
betweenCYP2C19 polymorphism and single-dose pharmaco-
kinetics of oral pantoprazole in healthy volunteers.
Materials and methods
Subjects
In the first part of the study 120 healthy, unrelated volun-
teers of Caucasian origin, Polish nationality (52 males and
68 females; age rank 20–27 years) were genotyped for
CYP2C19 polymorphism. Informed consent was obtained
from all participants. The study was approved by the Ethics
Committee of Pomeranian Medical University, Szczecin,
Poland. Within the genotyped group, 46 subjects were ho-
mozygous: 38 for the CYP2C19*1 allele, 6 for the
CYP2C19*17 allele, and 2 for the CYP2C19*2 allele.
Seventy-four were heterozygous with the following
CYP2C19 genotypes: 20 participants with *1/*2, 38 with
*1/*17, and 16 with *2/*17 genotypes.
In the second part of the study pharmacokinetics of
pantoprazole after a single oral dose of 40 mg in 32 healthy
volunteers defined for specific CYP2C19 genotypes was
determined. Subject characteristics and genotypes are
shown in Table 1.
Genotyping
CYP2C19 genotyping was performed in all study subjects.
Genomic DNA was extracted from 200 μL of whole blood
samples using GeneMATRIX Quick Blood DNA Purifica-
tion Kit (EURx, Poland). Each individual was genotyped for
a presence of SNPs marking CYP2C19 variant alleles:
rs4244285 (681 G>A) for allele *2, and rs12248560
(−806 C>T) for allele *17. The allelic discrimination Taq-
Man real-time PCR assays (Assay IDs: C_25986767_70,
C_469857_10, Applied Biosystems, USA) were used for
detection. Fluorescence data were captured using an ABI
PRISM 7500 FAST Real-Time PCR System (Applied Bio-
systems), after 40 cycles of PCR.
Drug concentration analysis
Pantoprazole concentration in plasma was determined by a
validated high-performance liquid chromatography method
(HPLC) with ultraviolet detection following solid phase
extraction [11]. The chromatographic system consisted of
a pump HP 1100, autosampler HP 1100, an ultraviolet
detector HP 1100 and DAD detector Agilent 1100. The
isocratic mobile phase was composed of a buffer solution
consisting of 25 mM potassium phosphate monobasic in
water containing 0.25% triethylamine and acetonitrile
(35:65% v/v). The pH06.5 was adjusted with phosphoric
acid. The mobile phase was pumped at an isocratic flow rate
of 1 mL/min at a temperature of 25°C. The wavelength of
UV detection was set at 290 nm. Chromatographic separa-
tions were achieved on Supelcosil LC-8-DB column (5 μm,
15 × 4.6 mm). Solid-phase extraction was used to extract the
pantoprazole and tinidazole as an internal standard. Recov-
eries from human plasma were≥90% for pantoprazole. The
lower limit of detection (LOD) at a signal:noise ratio 3:1
was 0.012 mg/L and the lower limit of quantitation for
pantoprazole was 0.025 mg/L. Intra- and interassay coeffi-
cients of variation were consistently ≤10% for plasma pan-
toprazole concentrations within the range of linearity. No
interfering peaks from metabolites of pantoprazole and en-
dogenous compounds were observed at the retention time of
analytes. All study samples were analyzed within 3 months
of their collection.
Pharmacokinetic study
Pharmacokinetic parameters of pantoprazole such as clear-
ance/F (CL/F, where F is the systemically available fraction
of a dose), volume of distribution (Vz/F), terminal half-life
(t½), mean residence time (MRT), time to maximum con-
centration (tmax), and the maximum concentration (Cmax)
were derived by noncompartmental analysis using Phoenix
WinNonlin 6.2 (Pharsight Corporation, Mountain View,
CA, USA). For each individual the terminal elimination rate
constant (lz) was determined by log-linear regression of the
terminal phase of the plasma concentration–time curve. The
area under the concentration–time curve (AUC) was deter-
mined by the linear trapezoidal rule from time zero to the
time of the last observed concentration [12].
1268 Eur J Clin Pharmacol (2012) 68:1267–1274
Differences between genotypes were evaluated using t
test for independent samples. The level of significance was
set at 0.05.
Population pharmacokinetic modeling
Because it was impossible to assess statistically the influ-
ence of rare genotypes, e.g., CYP2C19*2/*2 on pharmaco-
kinetics of pantoprazole using standard statistical tests, an
attempt was made to evaluate the impact of CYP2C19*2 and
CYP2C19*17 genotypes when included in the population
pharmacokinetic model as covariates.
To assess the influence of CYP2C19 genotypes on
pantoprazole pharmacokinetics, drug concentrations were
analyzed using the nonlinear mixed effects modeling
program, NONMEM (version V, level 1.1). The one-
and two-compartment models with first-order absorption
from the central compartment and a lag time were
tested. These models were implemented in the PREDPP
library subroutine ADVAN 2 TRANS 2 or ADVAN4
TRANS4 in NONMEM respectively. Pharmacokinetic
analysis was performed using the first-order (FO) esti-
mation method with post-hoc estimation of individual
parameters.
The intersubject variability in pharmacokinetic parame-
ters was estimated using an exponential model:
Pij ¼ TVP  expðηijÞ
where Pi is the jth pharmacokinetic parameter for the ith
subject, TVP is the typical value of jth parameter, ηij is a
random variable for the ith individual in the jth parameter. It
is assumed that the values of ηi are normally distributed with
a mean of zero and a variance of ω2.
Residual variability was described by a combined pro-
portional and additive error model:
COBS ¼ CPRED 1þ "1ð Þ þ "2
where COBS and CPRED are observed and predicted panto-
prazole concentrations, and ε1 and ε2 are the residual intra-




The possible relationship between the typical value of the
oral clearance (CL/F) and CYP2C19 genetic polymorphisms
was modeled according to the following equation:
TVCL=F ¼ θ1xθ2G1x :::::xθ6G5
where θ1 is the population value of oral clearance for the
wild-type group, θ2 - θ6 are the fractional changes in the oral
clearance for different genotypes, and G1 – G5 represent
CYP2C19 genotypes: *1/*2, *1/*17, *2/*17, *2/*2,
and*17/*17 respectively.
Model building was performed using a stepwise ap-
proach, adding an additional covariate at each step. The
effect of each covariate was evaluated based on changes in
the objective function value (OFV). The results were con-
sidered statistically significant if the decreases in OFV were
3.84 units (p<0.05), 6.63 units (p<0.01), and 10.83 units
(p<0.001). To assess the significance of each covariate a
backward elimination procedure was used. An increase in
OFV greater than 6.63 (P<0.01) was required to retain the
covariate in the final model.
The goodness-of-fit of each analysis was assessed by the
percentage relative standard error (%RSE) of the mean of
parameters estimates, changes in the estimates of intersub-
ject and residual variability, and visual inspection of scatter-
plots representing population (PRED) and individual
(IPRED) predicted concentrations versus observed concen-
trations and weighted residuals (WRES) versus predicted
pantoprazole concentrations. In addition, epsilon shrinkage
defined as 1-SD(IWRES) was calculated in order to ensure
validity of the diagnostics. Graphical diagnostics were
obtained using Visual-NM, v. V [13].
Results
Plasma concentration versus time profiles of pantoprazole in
healthy volunteers stratified according to the CYP2C19 gen-
otypes are presented in Fig. 1. Carriers of CYP2C19*2/*2
(n02) were characterized by considerably higher, starting
from 3.5 h post dose, plasma concentrations of pantoprazole
in comparison to wild-type (CYP2C19*1/*1; n06) volun-
teers. In subjects with the CYP2C19*17/*17 genotype (n06)
significantly lower plasma concentrations of the drug vs
Table 1 Subject characteristics
and CYP2C19 genotypes (n032) Parameter *1/*1 *1/*2 1/*17 *2/*2 *2/*17 *17/*17
Gender
(male/female)
6 (3/3) 6 (3/3) 6 (3/3) 2 (2/0) 6 (3/3) 6 (3/3)
Age (years) mean
(range)
23 (21–26) 22 (20–24) 23 (22–24) 23 (22,24) 24 (23–26) 24 (23–25)
Weight (kg) mean
(range)
75 (56–90) 66 (53–78) 69 (56–83) 88 (80–96) 66 (52–76) 68 (53–81)
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CYP2C19*1/*1 (n06) carriers, were observed from 3.0 h after
oral pantoprazole administration. Carriers of CYP2C19*1/
*17 (n06) and CYP2C19*2/*17 (n06) displayed concentra-
tion–time curves comparable to wild-type subjects.
Changes in pantoprazole pharmacokinetics in subjects
with different CYP2C19 genotypes are also reflected in
altered pharmacokinetic parameters (Table 2). As in the case
of the drug concentrations, most prominent deviations from
wild-type genotype carriers were observed in CYP2C19*2/
*2 (n02) and CYP2C19*17/*17 (n06) subjects. In
CYP2C19*2/*2 (n02) volunteers a marked decrease in 1z
by 83.3%, prolongation of t½ by 572% and MRT by 259%, a
rise of AUC by 506% and Cmax by 32.3% respectively were
noted. In carriers of CYP2C19*17/*17 (n06) significant
reduction in MRT by 24.8% (p<0.05) was revealed. Sub-
jects with CYP2C19*1/*2 (n06) genotype were character-
ized by markedly higher Cmax by 32.3% (p<0.05) and a
significant increase in AUC by 146% (p<0.05).
Population modeling confirmed a strong influence of *1/*2,
*2/*2 and *17/*17 genotypes on the pharmacokinetics of
pantoprazole. Based on the goodness-of-fit criteria, serum
pantoprazole concentration versus time profiles were best de-
scribed by a two-compartment model with first-order absorp-
tion from the central compartment and a lag time. Following
preliminary analyses, the random effects were included on oral
clearance (CL/F), volume of the central compartment (Vc/F),
first order absorption rate constant (ka), and the absorption lag
time (tlag). Volume of peripheral compartment (Vp/F) and
intercompartmental clearance (Q/F) were the remaining model
parameters. As shown in Table 3, genetic polymorphism of
CYP2C19 significantly affected pantoprazole oral clearance.
Based on the changes in OFV, the strongest impact on this
parameter was observed in subjects with genotype *1/*2 and in
both homozygotes *2/*2, *17/*17, whereas in heterozygotes
CYP2C19*17 the effect was significant but less pronounced.
Fig. 1 Mean plasma concentration–time profiles in subjects with
different CYP2C19 genotypes after administration of 40 mg pantopra-
zole as a single oral dose. Concentrations of CYP2C19*17/* were
significantly different from CYP2C19*1/*1 at each time point starting
from 3.0 h post-dose. Number of subjects per group n06, except for
CYP2C19*2/*2 where n02
Table 2 Pharmacokinetic parameters of pantoprazole (mean±SD) in healthy volunteers according to the CYP2C19 genotypes
Parameter/genotype *1/*1 (n06) *1/*2 (n06) *1/*17 (n06) *2/*2 (n02) *2/*17 (n06) *17/*17 (n06)
λz , h
−1 0.60±0.22 0.43±0.11 0.71±0.14 0.10±0.01 0.46±0.06 0.79±0.36
[−0.354, 0.005]a [−0.357, 0.565] [−0.669, −0.347] [−0.549, 0.260] [−0.125, 0.497]
t½, h 1.27±0.41 1.69±0.37 1.01±0.17 7.27±0.92 1.53±0.20 0.99±0.29
[0.016, 0.823] [−0.846, 0.320] [5.052, 6.945] [−0.338, 0.857] [−0.653, 0.082]
tmax, h 2.42±0.49 3.00±0.63 2.83±0.75 3.25±1.06 2.75±0.42 1.96±0.33
[−0.002, 1.168] [−0.436, 1.269] [−0.266, 1.933] [−0.396, 1.063] [−0.892, −0.025]
Cmax, mg/L 1.61±0.35 2.13±0.43* 1.30±0.29 1.91±0.07 1.86±0.55 1.30±0.55
[0.116, 0.931] [−0.919, 0.303] [0.036, 0.547] [−0.476, 0.974] [−0.780, 0.173]
AUC, mg⋅h/L 3.00±1.02 4.38±1.00* 2.13±0.50 15.18±0.07 3.56±0.65 1.87±0.72
[0.333, 2.418] [−1.817, 0.067] [11.426,12.921] [−0.429, 1.548] [−2.043, −0.216]
Vz/F, L 25.03±4.63 22.92±6.14 28.48±8.16 27.65±3.61 25.39±5.42 31.88±9.23
[−7.721, 3.512] [0.715, 6.184] [−2.269, 7.513] [−2.060, 2.788] [−0.687, 14.393]
CL/F, L/h 15.22±7.13 9.55±2.20 19.71±4.75 2.64±0.01 11.55±2.14 24.41±9.71
[−11.125, −0.229] [1.854, 7.123] [−17.795, −7.382] [−6.006, −1.351] [0.382, 17.981]
MRT, h 3.39±0.55 4.03±0.44 3.53±0.68 8.78±0.52 3.78±0.34 2.55±0.19*
[0.062, 1.412] [−0.998, 0.952] [6.498, 9.716] [−0.492, 1.234] [−1.723, −0.477]
AUC, area under the (receiver operating characteristic) curve; Vz , volume of distribution ; CL/F, clearance/sysystematically available fraction of a
dose; MRT, mean residence time (MRT)
a 95% confidence interval (CI) on the difference between means
*p<0.05, Student’s t test, vs genotype *1/*1
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In addition, their inclusion in the model did not lead to a
decrease in interindividual variability in CL/F.When backward
deletion was performed, for genotypes *1/*17 and *2/*17
differences in OFV were less than 6.63 and, in consequence,
they were removed from the model (Table 3). The estimates of
final population model parameters are presented in Table 4.
When comparing the basic and the final model, the interindi-
vidual variability in CL was reduced from 92.95% to 35.92%
after addingCYP2C19*1/*2, *2/*2, and *17/*17 genotypes as
model covariates. As expected, the lowest population oral
clearance was assessed in the carriers of genotype 2*/2*
(3.68 L/h) and the highest value in subjects with genotype
*17/*17 (31.13 L/h). The value of this parameter for *1/*2
genotype was 8 L/h. None of other covariates, such as age,
gender, and body weight significantly influenced any of the
pharmacokinetic parameters of pantoprazole (data not shown).
Figures 2 and 3 represent the relationship between the
population (PRED) and the individual (IPRED) model
predicted pantoprazole concentrations versus observed
concentrations and weighted residuals (WRES) as a func-
tion of PRED plots respectively. From Figs. 2 and 3, it
seems that the final model where CYP2C19 genotypes
were included as covariates describes well concentration
versus time profiles of pantoprazole. This can be con-
firmed both by the plot representing IPRED versus ob-
served concentrations where the data points are aligned on
the identity line (Fig. 2), and by the WRES versus the
PRED relationship, which shows random scatter around
zero (Fig. 3). Moreover, calculated epsilon shrinkage was
low (12.6%), indicating that the diagnostic plot involving
IPRED is relevant.
Discussion
Definition of CYP2C19 polymorphism is important for clinical
practice as it was documented that the polymorphism is associ-
ated with the efficacy of the treatment of gastric acid-related
disorders, with better clinical outcome in poormetabolizers, i.e.,
carriers of the CYP2C19*2 and CYP2C19*3 allele [14–17].
However, the pharmacokinetic studies did not involve subjects
homozygous for the CYP2C19*17 allele, which seems to have
a clinically significant impact, as it was proven for antiplatelet
action of clopidogrel [18]. Sim et al. in the first report on the
CYP2C19*17 allele in reporter vector experiments found an
Table 3 Summary of the covariate model-building steps (G1-*1/*2,
G2-*1/*17, G3-*2/*17, G4-*2/*2, G5-*17/*17)
Model/estimate ηCL/F
(%CV)
OFVa LLDb p value
CL/F0 θ1 (basic model) −604.54 –
θ1 08.69 92.95
CL/F 0 θ1 × θ2
G1 −616.36 11.82 <0.001
θ107.51 110.91
θ200.203
CL/F 0 θ1 x θ2
G1 x θ3




CL/F 0 θ1 x θ2
G1 x θ3
G2 x θ4































a Objective function value
b Difference in the -2 log likelihood in relation to the model above
Table 4 Final population model estimates of pantoprazole
Parameter Estimate %RSE
CL/F, L/h 12.5 8.88a
Vc/F, L 8.66 35.80
ka , h
-1 1.09 28.44
tlag , h 1.45 0.99
Q/F, L/h 3.34 15.12










a Calculated as 100%xSE/estimate
b Calculated as 100%xSE(omega)/(2*estimate(omega)
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increased transcriptional activity of CYP2C19*17 allele in vivo
in mice [4]. The clinical part of the study revealed up to 50–
60% higher metabolic rates for omeprazole and mephenytoin in
homozygotes for CYP2C19*17 allele than subjects homozy-
gous for the CYP2C19*1 allele after a single dose of the drug.
Pantoprazole undergoes O-demethylation via CYP2C19,
followed by sulfate conjugation and sulfone/sulfide forma-
tion [17]. Having in mind widespread clinical application of
the drug it is very important to define the impact of CYP2C19
polymorphism on its pharmacokinetics. The completed stud-
ies recruited healthy volunteers and patients being carriers of
CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17.
However, the CYP2C19*17 allele was solely evaluated in a
heterozygous setting. The study of Sim et al. [4], as well as our
preliminary report [10], suggest that the CYP2C19*17/*17
state?? might significantly affect PPI pharmacokinetics. Sim
et al. [4] demonstrated a higher omeprazole/5-hydroxyome-
prazole metabolic ratio and Gawrońska-Szklarz et al. [10]
higher blood concentrations of pantoprazole attained 3 h after
oral drug administration in CYP2C19*17/*17 subjects in
comparison to wild-type CYP2C19*1/*1 homozygotes. Our
former study [10] evaluated pantoprazole concentration at a
single time point as stated above, giving only preliminary
information on CYP2C19 polymorphism effects on the drug
concentrations in patients stratified according to genotype
(however,CYP2C19*2/*2 patients were not available for drug
concentration studies). The present study analyzes pharmaco-
kinetic data that enable better definition of the role of the
CYP2C19 polymorphism in pantoprazole pharmacokinet-
ics, and also involves CYP2C19*2/*2 volunteers. It is
demonstrated that polymorphism of CYP2C19 affects
pharmacokinetics of pantoprazole. The impact was docu-
mented for CYP2C19*1/*2, CYP2C19*2/*2 , and
CYP2C19*17/*17 genotypes; however, statistical analysis
did not reveal any prominent effects of CYP2C19*1/17*
and CYP2C19*2/*17 genotypes. Carriers of the genotype
CYP2C19*2/*2 were characterized by higher drug concen-
trations beginning from 3.5 h after oral pantoprazole ad-
ministration, and an increase in AUC and MRT were seen
in CYP2C19*1/*2 and CYP2C19*2/*2 subjects compared
with CYP2C19 wild-type individuals. Also, a significantly
higher Cmax was observed in CYP2C19*1/*2 volunteers.
These findings are in line with the reports of Hunfeld et
al. [7, 8], who documented higher, although not signifi-
cantly different AUC, in CYP2C19*1/*2 patients in 2008
[7], and significant differences between CYP2C19*1/*2
and CYP2C19*1/*1 in 2010 [8]. Similar findings were
reported by Kearns et al. [9] from the pediatric population,
where AUC values for pantoprazole were significantly
elevated in CYP2C19*1/*2 children. Results from homo-
zygous CYP2C19*2 patients were also reported in the
aforementioned studies, i.e. Hunfeld et al. [7] found a
higher AUC of pantoprazole in those subjects, although
the differences did not reach statistical significance. Our
observations do confirm this finding, but at a statistically
Fig. 2 Population (upper panel) and individual (lower panel) models
predicted pantoprazole concentrations versus observed concentrations.
The solid line represents the line of unity
Fig. 3 Weighted residuals versus population model predicted panto-
prazole concentrations
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significant level, and the results are in keeping with pedi-
atric observations by Kearns et al. [9].
According to the results of the statistical analysis performed
in the present study heterozygosity for the CYP2C19*17 allele
does not affect the pharmacokinetics of pantoprazole. Both
subjects with CYP2C19*1/*17 and CYP2C19*2/*17 were
characterized with similar concentration–time curves and val-
ues of the calculated pharmacokinetic parameters as
CYP2C19*1/*1 carriers. These observations are in line with
the report by Hunfeld et al. [7], who did not find an effect of
CYP2C19*1/*17 on the AUC of the drug, and by Kearns et al.
[9] for CYP2C19*1/*17 and CYP2C19*2/*17 genotypes and
AUC of pantoprazole. Based on these reports and our own
results it can be concluded that heterozygosity for the
CYP2C19*17 allele do not affect considerably pantoprazole
kinetics.
Our population modeling confirmed the influence of the
*1/*2, *2/*2, and *17/*17 genotypes on the pharmacoki-
netics of pantoprazole. Based on the changes in objective
function value, a strong impact on pantoprazole oral clear-
ance was observed in both homozygotes *2/*2 and *17/*17,
whereas in genotype *1/*2 the effect was significant, but
less evident.
Our study is the first one evaluating an effect of
CYP2C19*17/*17 on pantoprazole plasma levels. It is
revealed that the drug concentrations in carriers of the
CYP2C19*17/*17 genotype are significantly higher than in
the CYP2C19 wild-type genotype beginning from 3 h after
single oral administration of 40 mg of the drug. The calcu-
lated pharmacokinetic parameters also demonstrate lower
drug accumulation and accelerated elimination in
CYP2C19*17/*17 vs. CYP2C19*1/*1 subjects. An effect
of CYP2C19*17 polymorphism was also evaluated for an-
other PPIs, i.e., omeprazole. In CYP2C19*17/*17 subjects,
it was found to influence the metabolic ratio of omeprazole/
5-hydroxyomeprazole [4] and had no effects on esomepra-
zole [19] and omeprazole [20] pharmacokinetics, whereas
for CYP2C19*17 heterozygosity no impact on omeprazole
pharmacokinetics was documented [7, 9].
Like the CYP2C19*17/*17 genotype, a prominent effect
of the CYP2C19*2/*2 genotype was observed in the present
study. Homozygous carriers of the CYP2C19*2 allele were
characterized by higher plasma levels of pantoprazole along
with a decreased λz, prolongation of MRT and t½, and a rise
in the AUC in comparison to the CYP2C19*1/*1 genotype.
Effects of poor CYP2C19 status on the pharmacokinetics of
other PPIs were also documented for omeprazole [7, 19, 20],
esomeprazole [8], rabeprazole [21], and lansoprazole [7, 21,
22].
These observations indicate that the CYP2C19 status
affects the pharmacokinetics of pantoprazole. Moreover,
our findings document that 57% of the intersubject variabil-
ity in pantoprazole clearance can be explained by the
CYP2C19 genotype status. The results also support clinical
observations indicating the variability of cure rates of gastric
acid-related disorders treated with pantoprazole. It was
found that the CYP2C19*2/*2 genotype was associated with
higher Helicobacter pylori eradication rates, whereas no
associations were noted for CYP2C19*1/*17 and
CYP2C19*17/*17 patients [23]. Our previous study also
indicated an influence of the CYP2C19 polymorphism on
Helicobacter pylori eradication, since carriers of *1/*1, *1/
*17, and *17/*17 were at a higher risk of treatment failure in
comparison to *2/*2, *1/*2, and *2/*17 patients [10].
The results of the present study suggest that CYP2C19
genotyping should be used as a predictor of pantoprazole
concentrations, and thus it may be useful as a dose adjust-
ment tool. However, it should be stated that the results of the
present study refer to single-dose pantoprazole pharmacoki-
netics, and an effect of CYP2C19 polymorphism on multiple
dosing should be addressed in further investigations.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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